Human arylamine N-acetyltransferase 2 polymorphism and susceptibility to allergic contact dermatitis

International Journal of Dermatology

Volumn 45, Issue 3, 2006, Pages 323-326

  Nacak, Muradiye ^a,b   Erbagci, Zulal ^a,b,c   Aynacioglu, A Sukru ^a,b  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Epidauros Biotechnologie AG   (Germany)

^c NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE; ARYLAMINE ACETYLTRANSFERASE; GUANINE NUCLEOTIDE; PHENYLENEDIAMINE; PYRIMIDINE NUCLEOTIDE;

ACETYLATION; ADOLESCENT; ADULT; AGED; ARTICLE; ATOPY; CANCER; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN CELL; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PATHOGENESIS; POINT MUTATION; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIZATION; SKIN ALLERGY;

ACETYLATION; ADOLESCENT; ADULT; AGED; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; COLORING AGENTS; DERMATITIS, ALLERGIC CONTACT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENYLENEDIAMINES; POINT MUTATION; POLYMORPHISM, GENETIC;

EID: 33644748199     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.02464.x     Document Type: Article

References (29)

1. Levy M, Caraco Y, Geisslinger G. Drug acetylation in liver disease. Clin Pharmacokinet 1998; 34: 219-226.
2. Nebert DW. Polymorphism in drug-metabolizing enzymes. what is their clinical relevance and why do they exist? Am J Hum Genet 1997; 60: 265-271.
3. Weber W.W., Hein D.W. N-Acetylation pharmacogenetics. Pharmacol Rev 1985; 37: 25-79.
4. O'Neil WM, Gilfix BM, DiGirolamo A, et al. N-acetylation among HIV positive patients with AIDS. When is fast, fast and slow, slow? Clin Pharmacol Ther 1997; 62: 261-271.
5. Blum M, Demierre A, Grant DM, et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991; 88: 5237-5241.
6. Vatsis KP, Martell KS, Weber WW. Diverse point mutations in human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA 1991; 88: 6333-6337.
7. Henry JL, Chun-Ya H, Bruce KL, et al. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (Nat2). Gen Pharmacogenetics 1994; 4: 125-134.
8. Weber WW. Acetylation. Birth Defects Orig Artic Ser 1990; 26: 43-65.
9. Chen J, Stampfer M.J., Hough H.L., et al. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res 1998; 58: 3307-3311.
10. Ladero JM, Agundez JA, Olivera M, et al. N-acetyltransferase 2 single-nucleotide polymorphisms and risk of gastric carcinoma. Eur J Clin Pharmacol 2002; 58: 115-118.
11. Cascorbi I, Brockmöller J, Mrozikiewicz PM, et al. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as susceptibility for lung cancer. Cancer Res 1996; 56: 3961-3966.
12. Schnuch A, Westphal GA, Muller MM, et al. Genotype and phenotype of N-acetyltransferase 2 (NAT2) polymorphisim in patients with contact allergy. Contact Dermatitis 1998; 38: 209-211.
13. Westphal GA, Reich K, Schulz TG, et al. N-acetyltransferase 1 and 2 polymorphisms in para-substituted arylamine-induced contact allergy. Br J Dermatol 2000; 142: 1121-1127.
14. Nacak M, Aynacioglu AS, Filiz A, et al. Association between the N-acetylation genetic polymorphism and bronchial asthma. Br J Clin Pharmacol 2002; 54: 671-674.
15. Zielinska E, Niewirowski W, Bodalski J, et al. Arylamine N-acetyltransferase (NAT2) gene mutations in children with allergic diseases. Clin Pharmacol Ther 1997; 62: 635-642.
16. Krasteva M, Kehren J, Sayag M, et al. Contact dermatitis II. Clinical aspects and diagnosis. Eur J Dermatol 1999; 9: 144-159.
17. Kawakubo Y, Merk HF, Masaoudi TA, et al. N-Acetylation of paraphenylenediamine in human skin and keratinocytes. J Pharmacol Exp Ther 2000; 292: 150-155.
18. Kawakubo Y, Manabe S, Yamazoe Y, et al. Properties of cutaneous acetyltransferase catalyzing N- and O-acetylation of carcinogenic arylamines and N-hydroxyarylamine. Biochem Pharmacol 1988; 37: 265-270.
19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extraction DNA from human nucleated cells. Nuc Acid Res 1988; 16: 1215.
20. Cascorbi I, Drakoulis N, Brockmöller J, et al. Arylamine N-acetyltransferase mutations and their allelic linkage in unrelated Caucasion individuals: Correlation with phenotypic activity. Am J Hum Genet 1995; 57: 581-592.
21. Krasteva M, Nicolas JF, Chabeau G, et al. Dissociation of allergic and immunogenic functions in contact sensitivity to paraphenylenediamine. Int Arch Allergy Immunol 1993; 102: 200-204.
22. Griem P, Wulferink M, Sachs B, et al. Allergic and autoimmune reactions to xenobiotics: How do they arise? Immunol Today 1998; 19: 133-141.
23. Anderson C, Hehr A, Robbins R, et al. Metabolic requirements for induction of contact hypersensitivity to immunotoxic polyaromatic hydrocarbons. J Immunol 1995; 155: 3530-3537.
24. Bandman O, Vaughan J, Holmans P, et al. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 1997; 350: 1136-1139.
25. Aynacioglu AS, Cascorbi I, Mrozikiewicz PM, et al. Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population. Pharmacogenetics 1997; 7: 327-331.
26. Mrozikiewicz PM, Cascorbi I, Brockmöller J, et al. Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetytransferase gene in the Polish population. Clin Pharmacol Ther 1996; 59: 376-382.
27. Mashimo M, Suzuki T, Abe M, et al. Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum Genet 1992; 90: 139-143.
28. Foy V, Weinkauf R, Whittle E, et al. Ethnic variation in the skin irritation response. Contact Dermatitis 2001; 45: 346-349.
29. Kawakubo Y, Nakamori M, Schöpf E, et al. Acetylator phenotype in patients with p-Phenylenediamine allergy. Dermatology 1997; 195: 43-45.